

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA voxelotor for treating haemolytic anaemia caused by sickle cell disease [ID1403]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | | |
|---|---|
| 1. | Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| It was highlighted during scoping that: | |
| <ul style="list-style-type: none">• Sickle cell disease mainly affects people of African, Caribbean, Middle Eastern or South Asian family background• People with sickle cell disease may be registered as disabled• There is a socioeconomic imbalance among people with sickle cell disease | |
| 2. | Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| It was highlighted that people with sickle cell disease consider that the condition is not widely understood, including among healthcare professionals, which often results in poor hospital care and stigma around seeking pain relief for crises. | |
| It was also highlighted that there is a high unmet need and limited access to new safe, effective treatments for SCD which widens health inequalities for the SCD community | |

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No other equalities issues were identified by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?

Equality issues considered by the committee are included in section 3.18 of the draft guidance document.

Approved by Associate Director (name): Linda Landells.....

Date: 19 December 2022

Final draft guidance

(when draft guidance issued)

1.	Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?
In response to consultation, it was highlighted that: <ul style="list-style-type: none">voxelotor may contribute towards reducing the stigma around seeking pain relief	
2.	If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
Not applicable	
3.	If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
Not applicable	
4.	If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
Not applicable	

5. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?
Equality issues considered by the committee are included in section 3.18 of the Final Draft Guidance document

Approved by Associate Director (name): Linda Landells.....

Date: 7 July 2023